Archives
- 2018-07
- 2018-10
- 2018-11
- 2019-04
- 2019-05
- 2019-06
- 2019-07
- 2019-08
- 2019-09
- 2019-10
- 2019-11
- 2019-12
- 2020-01
- 2020-02
- 2020-03
- 2020-04
- 2020-05
- 2020-06
- 2020-07
- 2020-08
- 2020-09
- 2020-10
- 2020-11
- 2020-12
- 2021-01
- 2021-02
- 2021-03
- 2021-04
- 2021-05
- 2021-06
- 2021-07
- 2021-08
- 2021-09
- 2021-10
- 2021-11
- 2021-12
- 2022-01
- 2022-02
- 2022-03
- 2022-04
- 2022-05
- 2022-06
- 2022-07
- 2022-08
- 2022-09
- 2022-10
- 2022-11
- 2022-12
- 2023-01
- 2023-02
- 2023-03
- 2023-04
- 2023-05
- 2023-06
- 2023-07
- 2023-08
- 2023-09
- 2023-10
- 2023-11
- 2023-12
- 2024-01
- 2024-02
- 2024-03
- 2024-04
- 2024-05
- 2024-06
- 2024-07
- 2024-08
- 2024-09
- 2024-10
- 2024-11
- 2024-12
- 2025-01
- 2025-02
- 2025-03
-
br Conclusion These studies broadly demonstrate that
2024-09-20
Conclusion These studies broadly demonstrate that dopamine and endocannabinoid signaling in the NAc can have diverse effects on AMPAR-mediated synaptic function depending on previous psychostimulant experience. Here, we examined mechanisms underlying the depotentiation of AMPAR-mediated synaptic
-
br Conclusion br Acknowledgement This
2024-09-20
Conclusion Acknowledgement This study was supported by NIH/NINDSR01 NS036812-16. Introduction Lipoxygenases (LOXs) are a heterogeneous family of enzymes that catalyze the peroxidation of polyunsaturated fatty acids (PUFAs). By oxidizing free PUFAs, they were shown to contribute to the gene
-
br Current therapies for metabolic diseases Inborn
2024-09-20
Current therapies for metabolic diseases Inborn errors of metabolism caused by deficiency of particular enzymes due to loss of function mutations or deletions have been treated by decreasing the intake of the enzymatic substrate, supplementation with an essential cofactor or vitamin, increasing m
-
Thus far clinical data indicate that IDO inhibitors
2024-09-20
Thus far, clinical data indicate that IDO1 inhibitors have manageable toxicity, albeit with a relatively short period of treatment in a small number of patients. KYN is a pluripotent mediator and key intermediate for the synthesis of a host of downstream KP metabolites that are implicated in inflamm
-
br Conflict of interest br Acknowledgements
2024-09-20
Conflict of interest Acknowledgements We would like to thank Editage (www.editage.jp) for English language editing. This work was supported by Grants-in-Aid for Scientific Research, Japan Society for the Promotion of Science, Grant Number 24592576. Co-existence of β- and β-adrenergic recept
-
Regarding brain tumors AXL has been implicated in gliomagene
2024-09-19
Regarding Aldicarb tumors, AXL has been implicated in gliomagenesis and chemoresistance [39]. Previous investigations found that AXL is constitutively phosphorylated in many glioma cell lines, murine xenograft tumors and primary patient tumor samples [40]. Immunohistochemical analysis of AXL and Ga
-
br Autophagy at the Synapse The synapse is a highly
2024-09-19
Autophagy at the Synapse The synapse is a highly specialized neuronal compartment that forms the basic unit of communication between neurons. Communication relies on electrical signals that are propagated down the axon of the presynaptic neuron, where they trigger the quantal release of neurotran
-
ATM is generally regarded to be the principal
2024-09-19
ATM is generally regarded to be the principal mediator of the G1 fccp synthesis checkpoint, whereas the induction of the intra-S-phase and G2/M checkpoints are usually primarily related to ATR function. However, several studies have demonstrated that, depending on the cellular context and type of DN
-
br Conflict of interest br Introduction Platelets are
2024-09-19
Conflict of interest Introduction Platelets are anucleate blood cells essential for hemostasis and wound healing; tight regulation of platelet numbers is crucial for human health. Platelets are synthesized and released from bone marrow megakaryocytes into the circulation where they remain for
-
br Conclusions The present protocol for localizing or spotti
2024-09-19
Conclusions The present protocol for localizing or “spotting” the site of action of an antioxidant in a micro-heterogeneous medium is based on the differences in its reactivity vis-à-vis the series of amphiphobic TEMPO derivatives 1a–f. Plots of the relative antioxidant effectiveness of a given A
-
The RAS may have different
2024-09-18
The RAS may have different functions depending on whether we consider the circulatory component or the different local tissue systems (including brain) well described previously [29]. The cardiovascular control and hydroelectrolytic balance (among other functions), are largely the result of the infl
-
In hypothalamus as indicated in Fig column A
2024-09-18
In hypothalamus, as indicated in Fig. 2 (column A) and following the enzymatic cascade represented in Fig. 1, we could hypothesize a predominance of Ang 2–10 and Ang III formation in SHR compared to WKY. This is in agreement with previous results that reported significant higher rate of Ang 2–10 for
-
While the mechanisms by which ALDH regulates cardiac respons
2024-09-18
While the mechanisms by which ALDH2 regulates cardiac responses to pathological stress remain unclear, the capillary rarefaction found in pressure-overloaded ALDH2 Tg hearts provides potential clues. Loss of capillary density and diminished endothelial function occur in pathological hypertrophy [46]
-
nucleoside analogs Differentiation of skeletal myoblasts is
2024-09-18
Differentiation of skeletal myoblasts is a tightly orchestrated process that involves myoblast proliferation, nucleoside analogs withdrawal, expression of muscle-specific genes, and fusion into multinucleated myofibers (Horsley and Pavlath, 2004; Krauss, 2010). The maintenance of muscle mass is imp
-
br Conclusion br Conflict of Interest br Author Contribution
2024-09-18
Conclusion Conflict of Interest Author Contributions Acknowledgements This work was supported by a research grant (SR/50/AS-14/2012) from the Department of Science and Technology, New Delhi, India to CMC and CSIR Senior Research Fellowship (09/013(0339)/2010-EMR-I) to SB. Introduction
15918 records 80/1062 page Previous Next First page 上5页 7677787980 下5页 Last page